These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24478404)

  • 1. Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease.
    Jansson M; Beissner M; Phillips RO; Badziklou K; Piten E; Maman I; Sarfo FS; Huber KL; Rhomberg A; Symank D; Wagner M; Wiedemann F; Nitschke J; Banla Kere A; Herbinger KH; Adjei O; Löscher T; Bretzel G
    J Clin Microbiol; 2014 Apr; 52(4):1246-9. PubMed ID: 24478404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sensitive detection of Mycobacterium ulcerans by use of a loop-mediated isothermal amplification test.
    Njiru ZK; Yeboah-Manu D; Stinear TP; Fyfe JA
    J Clin Microbiol; 2012 May; 50(5):1737-41. PubMed ID: 22357495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buruli ulcer disease in Republic of the Congo.
    Marion E; Obvala D; Babonneau J; Kempf M; Asiedu KB; Marsollier L
    Emerg Infect Dis; 2014 Jun; 20(6):1070-2. PubMed ID: 24857328
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of Mycobacterium ulcerans by the loop mediated isothermal amplification method.
    Ablordey A; Amissah DA; Aboagye IF; Hatano B; Yamazaki T; Sata T; Ishikawa K; Katano H
    PLoS Negl Trop Dis; 2012; 6(4):e1590. PubMed ID: 22509415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana.
    Beissner M; Awua-Boateng NY; Thompson W; Nienhuis WA; Klutse E; Agbenorku P; Nitschke J; Herbinger KH; Siegmund V; Fleischmann E; Adjei O; Fleischer B; van der Werf TS; Loscher T; Bretzel G
    Am J Trop Med Hyg; 2010 Nov; 83(5):1059-65. PubMed ID: 21036838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans.
    Yemoa A; Gbenou J; Affolabi D; Moudachirou M; Bigot A; Anagonou S; Portaels F; Quetin-Leclercq J; Martin A
    Planta Med; 2011 Apr; 77(6):641-6. PubMed ID: 21240839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
    Guarner J
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular detection of Mycobacterium ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of maritime region in Togo.
    Maman I; Tchacondo T; Kere AB; Beissner M; Badziklou K; Tedihou E; Nyaku E; Amekuse K; Wiedemann FX; Karou DS; Bretzel G
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006455. PubMed ID: 29782522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs.
    Owusu E; Newman MJ; Akumwena A; Bannerman E; Pluschke G
    BMC Microbiol; 2017 Jan; 17(1):2. PubMed ID: 28056807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.
    Marsollier L; Honoré N; Legras P; Manceau AL; Kouakou H; Carbonnelle B; Cole ST
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1228-32. PubMed ID: 12654651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quick and cost effective method for the diagnosis of Mycobacterium ulcerans infection.
    de Souza DK; Quaye C; Mosi L; Addo P; Boakye DA
    BMC Infect Dis; 2012 Jan; 12():8. PubMed ID: 22257432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens.
    García-Sierra N; Lacoma A; Prat C; Haba L; Maldonado J; Ruiz-Manzano J; Gavin P; Samper S; Ausina V; Domínguez J
    J Clin Microbiol; 2011 Oct; 49(10):3683-6. PubMed ID: 21813715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens.
    Durnez L; Stragier P; Roebben K; Ablordey A; Leirs H; Portaels F
    J Microbiol Methods; 2009 Feb; 76(2):152-8. PubMed ID: 18973778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Painful Buruli ulcer in a Malian visitor to France.
    Ezzedine K; Pistone T; Guir V; Malvy D
    Acta Derm Venereol; 2010 Jul; 90(4):424. PubMed ID: 20574617
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppy molecular beacon melting temperature coding.
    Chakravorty S; Kothari H; Aladegbami B; Cho EJ; Lee JS; Roh SS; Kim H; Kwak H; Lee EG; Hwang SH; Banada PP; Safi H; Via LE; Cho SN; Barry CE; Alland D
    J Clin Microbiol; 2012 Jul; 50(7):2194-202. PubMed ID: 22535987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.